Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15143001 | 1.00 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL17816948 | 1.00 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL3192032 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL98457 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL5575317 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL6206953 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL6479731 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL223631 | 0.85 | POLB (0.59) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL7158782 | 0.83 | POLB (0.58) | POLBGAAALOX12HTTKMT2A | |
| SCHEMBL20123343 | 0.83 | POLB (0.58) | POLBGAAALOX12HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230266666-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-24 | — | — | US | disclosed |
| EP-3421449-B1 | PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVES | UNIV KYOTO (JP) | 2021-03-31 | — | — | EP | disclosed |
| EP-3421449-A1 | PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVE, AND 1,1'-BINAPHTHYL DERIVATIVE | Kyoto University (JP) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017145716-A1 | PRODUCTION METHOD FOR 1,1'-BINAPHTHYL DERIVATIVE, AND 1,1'-BINAPHTHYL DERIVATIVE | 国立大学法人京都大学 | 2017-08-31 | — | — | WO | disclosed |
| US-9017919-B2 | Resist composition, method of forming resist pattern, novel compound and acid generator | TOKYO OHKA KOGYO CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9017919-B2 | Resist composition, method of forming resist pattern, novel compound and acid generator | TOKYO OHKA KOGYO CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20120135347-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, POLYMERIC COMPOUND AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120107744-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND AND ACID GENERATOR | TOKYO OHKA KOGYO CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-1371646-B1 | ARYL-SUBSTITUTED ALICYCLIC COMPOUND AND MEDICAL COMPOSITION COMPRISING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2010-05-19 | — | — | EP | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
| US-7332500-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107744-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, NOVEL COMPOUND AND ACID GENERATOR | SLC11A2, ABCC1, ASIC1 | POLB 90/4885GAA 2732/4885ALOX12 217/4885 |
| US-20120135347-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, POLYMERIC COMPOUND AND COMPOUND | RER1, ABCC1, GAR1 | POLB 439/4885GAA 2469/4885ALOX12 370/4885 |
| US-20230266666-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | H1-0, H1-4, CHRM1 | POLB 1933/4885GAA 4204/4885ALOX12 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.